SAN DIEGO— Freedom Meditech, a medical device company commercializing non-invasive ophthalmic technologies for the detection of disease and management of patient health, announced the appointment of Paul M. Karpecki, OD, FAAO, to the Scientific Advisory Board.

The company also announced that it will be providing free demonstrations of the ClearPath DS-120, an FDA cleared device for measuring autofluorescence in the lens of the eye, at the 116th Annual AOA Congress & 43rd Annual AOSA Conference being held in San Diego June 26 to 30.

“Freedom Meditech is innovating the routine optometry visit through the introduction of new technologies that enable optometrists to advance their patient’s overall health,” said Karpecki. “I am joining the scientific advisory board at an exciting time for the company as it prepares to introduce optometrists to ClearPath DS-120. Detecting autofluorescence in the crystalline lens of the eye, which has been tied to biomarkers associated with diabetes, represents an important and valuable new health offering optometrists can consider during an eye exam.”

Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in cornea and refractive surgery at Hunkeler Eye Centers in affiliation with the Pennsylvania College of Optometry. He currently works in corneal services, heads the ocular surface disease clinic and is director of clinical research at the Koffler Vision Group in Lexington, Ky.

Karpecki was one of two optometrists appointed to the Delphi International Society at Wilmer-Johns Hopkins, which included the top 25 dry eye experts in the world and the National Eye Institute’s Dry Eye Committee to provide insights around dry eye and women. A noted educator and author, he is the chief medical editor and vice president of clinical content for the Review of Optometry Journal. He also serves on the board for the charitable organization Optometry Giving Sight.